An early study has indicated that it affects approximately half of AML (53.3%) patients [80], while another report indicated that TERT dysregulation is present in all acute promyelocytic leukemia (APL, AML-M3) patients in their cohort [81]. The gene discussed is TERT; the disease is acute myeloid leukemia.